Data Sheet 4_Quality appraisal of clinical practice guidelines for attention deficit hyperactivity disorder: a systematic review using the appraisal of guidelines for research and evaluation (AGREE II) instrument.pdf

ObjectivesAttention deficit hyperactivity disorder (ADHD) can significantly impact multiple life conditions across the lifespan. Reliable clinical practice guidelines (CPGs) are crucial for the clinical decision-making for the diagnosis and management of ADHD. This study aimed to assess the quality of current CPGs for the diagnosis and management of ADHD.
MethodsWe conducted a systematic literature search within Pubmed, Google Scholar, the Agency for Healthcare Research and Quality, Dynamed, the National Institute for Health and Care Excellence (NICE), the National Health and Medical Research Council (NHMRC), and other local and online databases started January 19, 2022. We assessed the guideline quality using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument. All of the included guidelines were critically appraised by five independent reviewers. We also evaluated the interrater reliability of each AGREE II domain and the overall domain score by calculating the intraclass correlation coefficient (ICC) using IBM SPSS Statistics version 28.
ResultsA total of 11 CPGs were included in the study. The majority of the CPGs achieved the highest score in domain 4 “Clarity of Presentation” (mean ± standard deviation, 73.73% ± 12.5%). The domains that achieved the lowest scores were domains 5 “Applicability” (mean ± standard deviation, 45.18% ± 16.4%) and 3 “Rigor of Development” (mean ± standard deviation, 51.09% ± 24.1%). The American Academy of Pediatrics (AAP), NICE, and the Malaysian Health Technology Assessment Section (MAHTAS) CPGs were identified as the strongly recommended guidelines. All AGREE II domains yielded varied interrater reliability results; the full domain ICC ranged from 0.265 (95% confidence interval, −0.470 to 0.665) to 0.758 (95% confidence interval, 0.515 to 0.889).
ConclusionsOur appraisal indicated that the quality of current ADHD guidelines is varied, and three CPGs were classified as strongly recommended. Our findings offer relevant healthcare providers valuable insight into the appropriate selection of ADHD guidelines in clinical practice.
Systematic review registrationhttps://inplasy.com/inplasy-2022-8-0001/, identifier INPLASY202280001

**目的** 注意缺陷多动障碍（Attention Deficit Hyperactivity Disorder, ADHD）会对个体全生命周期的多项生活状态造成显著负面影响。可靠的临床实践指南（Clinical Practice Guidelines, CPGs）对ADHD的诊断与管理相关临床决策至关重要。本研究旨在评估当前用于ADHD诊断与管理的CPGs的质量。

**方法** 本研究于2022年1月19日启动，在PubMed、Google Scholar、美国医疗保健研究与质量局（Agency for Healthcare Research and Quality）、Dynamed、英国国家卫生与临床优化研究所（National Institute for Health and Care Excellence, NICE）、澳大利亚国家健康与医学研究委员会（National Health and Medical Research Council, NHMRC）以及其他本地与在线数据库中开展了系统性文献检索。本研究采用指南研究与评价工具（Appraisal of Guidelines for Research and Evaluation, AGREE II）对指南质量进行评估。所有纳入的指南均由5名独立评审员进行严格评价。本研究还通过IBM SPSS Statistics 28版计算组内相关系数（Intraclass Correlation Coefficient, ICC），以此评估AGREE II各领域及总领域得分的评分者间信度。

**结果** 本研究共纳入11篇CPGs。大部分CPGs在第4领域“报告清晰度（Clarity of Presentation）”中获得最高分，均值±标准差为73.73%±12.5%。得分最低的领域为第5领域“适用性（Applicability）”（均值±标准差为45.18%±16.4%）与第3领域“开发严谨性（Rigor of Development）”（均值±标准差为51.09%±24.1%）。美国儿科学会（American Academy of Pediatrics, AAP）、NICE以及马来西亚卫生技术评估部门（Malaysian Health Technology Assessment Section, MAHTAS）的CPGs被评为强烈推荐指南。AGREE II各领域的评分者间信度结果存在差异；总领域ICC值范围为0.265（95%置信区间：-0.470~0.665）至0.758（95%置信区间：0.515~0.889）。

**结论** 本评价结果显示，当前ADHD相关指南的质量参差不齐，其中3篇CPGs被归类为强烈推荐指南。本研究结果可为相关医疗从业者在临床实践中合理选择ADHD指南提供有价值的参考依据。

**系统评价注册信息** https://inplasy.com/inplasy-2022-8-0001/，注册标识符为INPLASY202280001